This represents the first oral HER2-selective, irreversible tyrosine kinase inhibitor (TKI), which was approved for this molecularly defined NSCLC subset in the US (Heymach et al., 2025[50]). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.